The fifth revised edition of this highly successful book presents the most extensive enhancement since Using and Understanding Medical Statistics was first published 30 years ago. Without question, the single greatest change has been the inclusion of source code, together with selected output, for the award-winning, open-source, statistical package known as R. This innovation has enabled the authors to de-emphasize formulae and calculations, and let software do all of the ‘heavy lifting.’ This edition also introduces readers to several graphical statistical tools, such as Q-Q plots to check normality, residual plots for multiple regression models, funnel plots to detect publication bias in a meta-analysis and Bland-Altman plots for assessing agreement in clinical measurements. New examples that better serve the expository goals have been added to a half-dozen chapters. In addition, there are new sections describing exact confidence bands for the Kaplan-Meier estimator, as well as negative binomial and zero-inflated Poisson regression models for over-dispersed count data. The end result is not only an excellent introduction to medical statistics, but also an invaluable reference for every discerning reader of medical research literature.

Contents
Preface to the Fifth Edition
Prefaces to the Previous Editions
• Basic Concepts
• Tests of Significance
• Fisher’s Test for 2 × 2 Contingency Tables
• Approximate Significance Tests for Contingency Tables
• Some Warnings concerning 2 × 2 Tables
• Kaplan-Meier or ‘Actuarial’ Survival Curves
• The Log-Rank or Mantel-Haenszel Test for Comparing Survival Curves
• An Introduction to the Normal Distribution
• Analyzing Normally Distributed Data
• Linear Regression Models for Medical Data
• Binary Logistic Regression
• Regression Models for Count Data
• Proportional Hazards Regression
• The Analysis of Longitudinal Data
• Analysis of Variance
• Data Analysis
• The Question of Sample Size
• The Design of Clinical Trials
• Further Comments regarding Clinical Trials
• Meta-Analysis
• Epidemiological Applications
• Diagnostic Tests
• Agreement and Reliability
References
Subject Index

Matthews, D.E. (Waterloo, Ont.);
Farewell, V.T. (Cambridge)
Using and Understanding Medical Statistics
5th, revised and extended edition
XX + 338 p., 48 fig., 103 tab., 2015
CHF 49.00 / EUR 46.00 / USD 54.00
(hard cover + online supplementary material)
Online version for institutional purchase
Prices subject to change, VAT not included
EUR price for eurozone countries, USD price for USA and Latin America only
(hard cover + online supplementary material)

eBook available on:

Dear Librarian
I have reviewed this publication and would like to recommend it for our library
Recommended by:

Department:

Date:

Signature:

Orders may be placed with any bookshop, subscription agency, directly with the publisher or through a Karger distributor.
Chemotherapy

International Journal of Experimental and Clinical Chemotherapy

Founded 1959 as ‘Chemotherapia’ by H.P. Kuenmerle and P. Rentchnick

Editor-in-Chief
G. Minotti, Rome

Associate Editors
G. Delogu, Rome
G. Graziani, Rome

Editorial Board
A.M. Biroccio, Rome
C. Chiesa, Rome
S. Gemma, Siena
S. Horkovics-Kovats, Kundl
S. Kohno, Nagasaki
C. Landersdorfer, Parkville, Vic.
P. Linder, Geneva
K. Machka, Munich
P. Menna, Rome
E. Monti, Busto Arsizio
K.G. Naber, Straubing

R. Nau, Göttingen
P. Preziosi, Rome
E. Salvatorelli, Rome
M. Sanguinetti, Rome
G. Sava, Trieste
G.M. Shah, Quebec, Que.
F. Sörgel, Nuremberg-Heroldsberg
J.C. Stingl, Bonn
F. Van Bambeke, Brussels
M. Wilhelm, Nuremberg

Paul Ehrlich
1854–1915

The founder of chemotherapy
Submission

Before submission, please read the Guidelines for Authors for specific requirements for manuscript preparation. Manuscripts written in English are considered and should be submitted online at www.karger.com/che (a link leads you to the Submission Website).

Submission of an article implies author agreement with the below Conditions. To be considered for publication, all manuscripts must be accompanied by a cover letter signed by all authors stating that the work has not been published, nor is it under consideration elsewhere, and that all authors approve the submission.

A Copyright Transfer Form, available on the Submission Website, with the corresponding author’s original (handwritten) signature must be received by the editorial office. Please print and sign the form, and upload it during submission (or fax or scan and email) to make it legally binding.

Names, postal and e-mail addresses of 4 international experts in the appropriate area of research should accompany each manuscript. At the Editors’ discretion, scientist(s) selected from this list may be invited to act as referee(s). Referees suggested should not be from the same institution as the author.

Presentation of manuscripts should follow the Uniform Requirements for Manuscripts Submitted to Biomedical Journals [see International Committee of Medical Journal Editors. Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication (April 2010 version). Available from: http://www.ICMJE.org].

In case of problems with submission, please contact:

che@karger.com
S. Karger AG – Medical and Scientific Publishers
Editorial Office ‘Chemotherapy’
Allschwilerstrasse 10
CH – 4009 Basel (Switzerland)
Tel. +41 61 306 1361
Fax +41 61 306 1434

Conditions

All manuscripts are subject to editorial and peer review. Manuscripts are received with the explicit understanding that the work has not been published (wholly or in part), and is not under simultaneous consideration in any language elsewhere. Furthermore, all authors have made substantial contributions and confirm that they have seen and approved the manuscript submission. Submission of an article implies the transfer of the copyright from the author to Karger Publishers upon acceptance. Accepted papers become the permanent property of Chemotherapy and may not be reproduced by any means, in whole or in part, without the written consent of the publisher. It is the author’s responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications.

Conflict of Interest

Authors are required to disclose any sponsorship or fundings arrangements related to the research presented in the manuscript and any possible conflicts of interest. A possible conflict of interest does not preclude consideration of a manuscript for publication, but the Editor might consider it appropriate to publish the disclosed information with the paper. All forms of support and financial involvement should be listed in the Acknowledgements section of the paper. The cover letter should certify that all forms of conflict of interest by all authors were clearly identified in the text.

Ethics

Research must comply with the guidelines for human studies and animal welfare regulations. Manuscripts reporting studies on human subjects should include evidence that the research was ethically conducted in accordance with the Declaration of Helsinki (World Medical Association; http://www.wma.net/en/30publications/10policies/b3/in dex.html). In particular, authors should state in the Materials and Methods section that subjects have given their informed written consent and that the study protocol was approved by an appropriate ethics committee. All patients should be identified by numbers or aliases, not by their real names. Authors should also state that animal experimentation was approved by an independent ethics committee. Copies of these guidelines and policy statements must be available for review by the editors if necessary.

Plagiarism Policy

Whether intentional or not, plagiarism is a serious violation. Karger Publishers defines plagiarism as reproduction of another work with at least 25% similarity and without citation. If evidence of plagiarism is found before/after acceptance or after publication of the paper, the author will be offered a chance for rebuttal. If the arguments are not found to be satisfactory, the manuscript will be retracted and the author sanctioned from publishing papers for a period to be determined by the responsible Editor(s).

Sections

Authors should indicate in the cover letter which manuscript type is being submitted for publication:

Original Papers: Fully documented reports of original research that must describe full sets of significant, original experiments in current anti-infective and antitumor chemotherapy research. Abstract, Introduction, Materials and Methods, Results, and Discussion sections are required. Consideration for publication is based on originality, novelty, scientific soundness, and appropriate analysis (maximum 3,000 words, 80 references, plus tables/figures).

Reviews: Comprehensive, state-of-the-art papers covering a timely topic by experts in the field (maximum 4,000 words, plus tables/figures, references). Reviews are usually invited by the Editor but may be unsolicited. Authors are asked to contact the Editor-in-Chief before submission in order to avoid clashes with other pending reviews. All reviews are subject to peer review. An unstructured abstract of no more than 200 words is required.

Novel Insights from Clinical Practice: The journal only considers case reports that provide significant new insights into a clinical problem or with an extremely unusual clinical course. Submissions can be based around a case or a number of similar cases. The most important aspect of the presentation is that it should provide a new perspective on a recognized clinical scenario or may represent an entirely new clinical condition. The novel aspects of the case(s) may be in the phenotype, the presentation, the investigation and/or the management. The manuscript should contain an unstructured abstract (maximum 150 words), introduction, case report and discussion section (maximum 2,000 words, maximum 2 tables or figures). Boxes containing bullet points on Established Facts (what is already known) and Novel Insights (new information gained) are required on the first page of the report. These should highlight the novelty of the clinical observation.

Short Communications: Short reports, brief laboratory observations, and preliminary communications can be submitted for accelerated publication under Short Communications. They must present new findings of sufficient importance to justify their accelerated acceptance. Such communications should represent complete, original studies and should be arranged in the same way as full length manuscripts (maximum 1,600 words).

Letters to the Editor: Letters to the Editor are encouraged if they directly concern articles recently published in this journal. Accepted letters are published under the title “Letters to the Editor” and the Editors reserves the right to submit such letters to the authors of the articles concerned prior to publication in order to allow them to respond in the same issue of the journal. In exceptional cases, Letters to the Editor may also address data published in another journal or general subjects related to matters discussed in the journal. No abstract is required (maximum 1,200 words).

Arrangement

The preferred word processing program is MS-Word. The cover letter, the manuscript, the tables and the figures must be submitted in separate files. The manuscript file must contain all the text elements in the following order: title page, abstract and key words, main text, acknowledgments, references, table and figure legends. Tables and figures should be submitted as separate files according to the instructions below. Automatic line numbering should be used consecutively from the title page through to the final page. All pages should be numbered, starting from the title page, including tables, figure legends and figures.

Title page: The first page should contain the concise title of the article along with a short title for use as a running head, the full names of the authors and their affiliations (department, institute, hospital, university etc. where the work was conducted). The full postal address, telephone and fax numbers, as well as the e-mail address of the author to whom correspondence should be sent must be given at the bottom of the title page.

Key words: Please supply 3–10 key words that reflect the content of the paper.

Abstract: Each original paper needs an abstract of up to 250 words structured with subheadings as follows: Background/Aims, Methods, Results, Conclusions. Structured abstracts are not needed for Reviews and Novel Insights from Clinical Practice.

Footnotes: Footnotes should be avoided. When essential, they should be numbered consecutively and appear at the foot of the appropriate page.

Acknowledgements: Include all sources of funding for the research presented in the manuscript and substantive contributions of individuals regarding the research or manuscript. All possible conflicts of interest should also be given here.

Abbreviations: Abbreviations (with the exception of those clearly well-established in the field) should be explained when they are first used.

Units of measurement: Measurements should be expressed in SI units wherever possible.

Drug names: Use generic names of drugs (first letter: lowercase) whenever possible. Registered trade names (first letter: uppercase) should be marked with the superscript registration symbol ® or ™ when they are first used.

Abbreviations:

- Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Available from: http://www.ICMJE.org
- Instructions for Authors: Available from: www.karger.com/che_Guidelines

The Guidelines for Authors are available at: www.karger.com/che_Guidelines

KARGER

E-Mail: Mail@karger.com
www.karger.com

© 2016 S. Karger AG, Basel
The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publisher and the editor(s). The appearance of advertisements in the journal is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Subscription Rates: Subscriptions run for a full calendar year. Prices are given per year.

<table>
<thead>
<tr>
<th>Subscription</th>
<th>Print or Online</th>
<th>Print+Online combined</th>
</tr>
</thead>
<tbody>
<tr>
<td>Personal</td>
<td>CHF 1232.00</td>
<td>CHF 1280.00</td>
</tr>
<tr>
<td></td>
<td>EUR 1027.00</td>
<td>EUR 1066.00</td>
</tr>
<tr>
<td></td>
<td>USD 1257.00</td>
<td>USD 1305.00</td>
</tr>
<tr>
<td>Institutional</td>
<td>CHF 45.60 Europe, CHF 67.20 Overseas</td>
<td></td>
</tr>
<tr>
<td></td>
<td>EUR 40.80</td>
<td>EUR 62.40</td>
</tr>
<tr>
<td></td>
<td>USD 62.40</td>
<td>USD 87.00</td>
</tr>
</tbody>
</table>

Back Volumes and Single Issues: Information on availability and prices of single print issues and print or electronic back volumes can be obtained from Customer Service at service@karger.com.

Bibliographic Indices: This journal is regularly listed in bibliographic services, including Current Contents® and PubMed/MEDLINE.

Photocopying: This journal has been registered with the Copyright Clearance Center (CCC), as indicated by the code appearing on the first page of each article. For readers in the US, this code signals consent for copying of articles for personal or internal use, or for the personal or internal use of specific clients, provided that the stated fee is paid per copy directly to Copyright Clearance Center Inc.

Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publisher and the editor(s). The appearance of advertisements in the journal is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Change of Address: Both old and new address should be sent to the subscription source.

Photo of Paul Ehrlich on inner title page
Courtesy of the Paul-Ehrlich-Institute, Langen, Germany
Dear Librarian

I have reviewed this publication and would like to recommend it for our library.

Recommended by:

Department:

Date:

Signature:

Orders may be placed with any bookshop, subscription agency, directly with the publisher or through a Karger distributor.

A valuable update on the multifaceted functions of the PTS

PTS50 - The Prokaryotic Phosphoenolpyruvate: Sugar Phosphotransferase System

50 Years After Its Discovery

Editor

Milton H. Saier

Contents

Introduction

• The Bacterial Phosphotransferase System: New Frontiers 50 Years After Its Discovery: Saier Jr., M.H.

Review Article

• PTS 50 Past, Present and Future, or Diauxie Revisited: Lengeler, J.W.

Research Articles

• PTS-Mediated Regulation of the Transcription Activator MtrR from Different Species: Surprising Differences Despite Strong Sequence Conservation: Joyet, P.; Derkaoui, M.; Bourouai, H.; Deutscher, J.


• Fucose-Mediated Transcriptional Activation of the fcs Operon by FcsR in Streptococcus pneumonia: Manzoor, I.; Shafeeq, S.; Azfai, M.; Kuipers, O.P.

• Control of Transposon-Mediated Directed Mutation by the Escherichia coli Phosphoenolpyruvate-Sugar Phosphotransferase System: Saier Jr., M.H.; Zhang, Z.

Review Article

• The Phosphotransferase System in Solventogenic Clostridia: Mitchell, W.J.

Research Article

• A Search for Ribonucleic Antiterminator Sites in Bacterial Genomes: Not Only Antitermination?: Gordon, N.; Rosenblum, R.; Nussbaum-Shochat, A.; Eliahoo, E.; Amster-Choder, O.

Review Article

• Regulation of the Utilization of Amino Sugars by Escherichia coli and Bacillus subtilis: Same Genes, Different Control: Plumbridge, J.

Research Articles

• Cross-Talk between the Canonical and the Nitrogen-Related Phosphotransferase Systems Modulates Synthesis of the KdpFABC Potassium Transporter in Escherichia coli: Lüttmann, D.; Göpel, Y.; Görke, B.

• Modeling the Interplay of Pseudomonas putida ERA™ with the Potassium Transporter KdpFABC: Wolf, S.; Pfüger-Grau, K.; Kremling, A.

Review Article

• Inactivation of the PTS as a Strategy to Engineer the Production of Aromatic Metabolites in Escherichia coli: Carmona, S.B.; Moreno, F.; Bolivar, F.; Gosset, G.; Escalante, A.

Research Article


Review Article

• Strong Sequence Conservation: Surprising Differences Despite Surprising Differences Despite Strong Sequence Conservation: Joyet, P.; Derkaoui, M.; Bourouai, H.; Deutscher, J.

The easiest way to order: www.karger.com

Karger – Medical and Scientific Publishers
CH-4009 Basel, Switzerland
orders@karger.com; f +41 61 306 12 34
www.karger.com

Prices subject to change, VAT not included.

Online version for institutional purchase

CHF 62.00 / EUR 46.00 / USD 73.00 (online)

CHF 52.00 / EUR 59.00 / USD 61.00 (soft cover)

Listed in MEDLINE/PubMed


Special Topic Issue


In 1964 Saul Roseman first described the phosphotransferase system (PTS) – a novel sugar-phosphorylating system in Escherichia coli. This compendium results from an international meeting held in Göttingen, Germany, during the summer of 2014 to commemorate the 50th anniversary of his discovery. A number of active researchers with a focus on the PTS reported their most recent findings concerning the structures, functions, mechanisms of action and physiological consequences of this complex system. The numerous aspects of the PTS, including a discussion regarding its impact on bacterial physiology, pathogenesis and ecology, are presented in this up-to-date compendium, which will provide a valuable source of information for many years to come.

Researchers, students and teachers of the physiology of archaea and bacteria will find this compendium an essential source of reference. Additionally, biochemists and geneticists interested in the functions and mechanisms of complex enzymes, transport or regulatory systems in microbes will be fascinated by the complexity of the PTS.
GOTTFRIED SCHATZ

A MATTER OF WONDER

What Biology Reveals about Us, Our World, and Our Dreams

Where do we come from? Is our destiny determined by the genes we inherit? In this book Gottfried Schatz, the world-renowned biochemist and co-discoverer of mitochondrial DNA, gives lucid – albeit often surprising – answers to universal questions and takes the reader on a fascinating journey of discovery across the boundaries of scientific disciplines. With passion and a keen sense of wonder he draws on philosophy, cultural history and art to formulate his reflections on the mysteries of life. These essays on key issues in the natural sciences will appeal not only to scientists but to all inquisitive minds, regardless of educational and professional background.

KARGER

S. Karger AG, P.O. Box
CH–4009 Basel
(Switzerland)

Fax +41 61 306 12 34
E-Mail orders@karger.ch

www.karger.com

Monographs in Virology

Compact and thorough reference volumes for virologists and non-virologists alike

A skilful selection of topics of exceptional importance and a panel of acknowledged experts as authors have ensured an outstanding reputation for this series. Each monograph, centered on an active area of virologic research, provides a critical evaluation of recent progress and a useful commentary on the direction of future research. Characterized by a consistently high standard of scholarship and clear presentation of content, volumes in this series have proved their enduring value as convenient reference tools for both virologists working in the field and scientists working in allied areas.

Vol. 28: Prophylaxis and Early Detection of HPV-Related Neoplasia
Editor: Pfister, H. (Cologne)
VIII + 140 p., 27 fig., 21 in color, 13 tab., 2012
CHF 159.00 / EUR 151.00 / USD 191.00

Vol. 27: Avian Influenza
Editors: Klenk, H.-D.; Matrosovich, M.N. (Marburg); Stech, J. (Greifswald)
VIII + 294 p., 35 fig., 16 in color, 12 tab., 2005
CHF 249.00 / EUR 235.00 / USD 291.00 (hard cover)
CHF 299.00 / EUR 280.00 / USD 352.00 (online)
‘... An outstanding collection of articles that should have a place in every animal or human influenza research laboratory.’ Clinical Infectious Disease

Vol. 26: Herpes Zoster
Recent Aspects of Diagnosis and Control
Editors: Gross, G. (Rostock); Doerr, H.W. (Frankfurt)
x + 194 p., 52 fig., 24 in color, 18 tab., 2006
CHF 198.00 / EUR 185.00 / USD 230.00 (hard cover)
CHF 238.00 / EUR 222.00 / USD 280.00 (online)

Vol. 25: Models of Viral Hepatitis
Editors: von Weizsäcker, F. (Freiburg); Roggenkoh, M. (Essen)
x + 164p., 27 fig., 1 in color, 5 tab., 2005
CHF 162.00 / EUR 151.00 / USD 191.00 (hard cover)
CHF 194.00 / EUR 182.00 / USD 235.00 (online)
Contents
Respiration brings together the results of both clinical and experimental investigations on all aspects of the respiratory system in health and disease. Clinical improvements in the diagnosis and treatment of chest and lung diseases are covered, as are the latest findings in physiology, biochemistry, pathology, immunology and pharmacology. The journal includes classic features such as editorials that accompany original articles in clinical and basic science research, reviews and letters to the editor. Further sections are: The Eye Catcher, What’s Your Diagnosis?, New Insights from Clinical Practice and Guidelines. Respiration is the official journal of the Swiss Respiratory Society (SGP) and also home to the European Association for Bronchology and Interventional Pulmonology (EABIP), which occupies a dedicated section on Interventional Pulmonology in the journal. This modern mix of different features and a stringent peer-review process by a dedicated editorial board make Respiration a complete guide to progress in thoracic medicine.

Respiration
Founded: 1944
Category: Clinical Research
Field of Interest: Respiratory System

Listed in bibliographic services, including Journal Citation Reports, PubMed/MEDLINE, Embase, Amedeo

2016: Volumes 91, 92
6 issues per volume
Language: English
ISSN 0025–7931
e-ISSN 1423–0356

Impact Factor: 2.593

Selected contributions
- Principles of Rehabilitation and Reactivation: Interstitial Lung Disease, Sarcoidosis and Rheumatoid Disease with Respiratory Involvement: Holland, A.E.; Dowman, L.M.; Hill, C.J. (Melbourne, Vic.)
- Guideline for the Acquisition and Preparation of Conventional and Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Specimens for the Diagnosis and Molecular Testing of Patients with Known or Suspected Lung Cancer: van der Heijden, E.H.F.M. (Nijmegen); Casal, R.F. (Houston, Tex.); Trisolini, R. (Bologna); Steinfort, D.P. (Parkville, Vic.); Hwangbo, B. (Goyang); Nakajima, T. (Chiba); Gauld, H. (Copenhagen); Rossi, G. (Modena); Ferretti, M. (Ancona); Herth, F.F.J. (Heidelberg); Yung, R. (Baltimore, Md.); Krasnik, M. (Copenhagen) on behalf of the World Association for Bronchology and Interventional Pulmonology Task Force on Specimen Guidelines
- Exercise Training-Based Pulmonary Rehabilitation Program Is Clinically Beneficial for Idiopathic Pulmonary Fibrosis: Vainshelboim, B. (Petach Tikva/Porto); Oliveira, J. (Porto); Yehoshua, L.; Weiss, I. (Petach Tikva); Fox, B.D.; Fruchter, O.; Kramer, M.R. (Petach Tikva/Tel Aviv)
- The Importance of Continuity in Inhaler Device Choice for Asthma and Chronic Obstructive Pulmonary Disease: Bjermer, L. (Lund)
- Aerosolized Antibiotics for Non-Cystic Fibrosis Bronchiectasis: Rubin, B.K.; Williams, R.W. (Richmond, Va.)

More information at www.karger.com/res
Antimicrobial Section

Original Papers

249 Potential of Casiopeínas® Copper Complexes and Antituberculosis Drug Combination against Mycobacterium tuberculosis
Barbosa, A.R.; Caleffi-Ferracioli, K.R. (Maringá); Leite, C.Q.F. (São Paulo); Garcia-Ramos, J.C.; Toledano-Magaña, Y.; Ruiz-Azuara, L. (Mexico D.F.); Siqueira, V.L.D. (Maringá); Pavan, F.R. (São Paulo); Cardoso, R.F. (Maringá)

275 Antibiotic Resistance Patterns and a Survey of Metallo-β-Lactamase Genes Including bla-IMP and bla-VIM Types in Acinetobacter baumannii Isolated from Hospital Patients in Tehran
Aghamiri, S. (Lahijan); Amirmozafari, N. (Tehran); Fallah Mehrabadi, J. (Qom); Fouladtan, B. (Lahijan); Hanafi Abdar, M. (Tehran)

Novel Insights from Clinical Practice

236 Gemcitabine-Induced Subacute Cutaneous Lupus Erythematosus: A Case Report
Ben Zvi, M.; Vaknine, H.; Menczer, J.; Peled, O.; Ben Shem, E.; Schreiber, L.; Levy, T. (Holon/Tel Aviv)

Anticancer Section

Review

223 Drug Resistance to EGFR Inhibitors in Lung Cancer
Tetsu, O.; Hangauer, M.J.; Phuchareon, J.; Eisele, D.W.; McCormick, F. (San Francisco, Calif.)

Original Papers

240 Second-Line Intraperitoneal Chemotherapy for Recurrent Epithelial Ovarian, Tubal and Peritoneal Cancer: A Propensity Score-Matching Study
Lu, C.-H.; Chang, Y.-H.; Lee, W.-H.; Chang, Y.; Peng, C.-W. (Taichung/Taipei); Chuang, C.-M. (Taipei); Task Force on Intraperitoneal Chemotherapy of Ovarian Cancer

256 Weight Loss Associated with Platinum-Based Chemotherapy in Patients with Advanced Lung Cancer

262 Efficacy and Safety Assessment of Paclitaxel in Patients with Docetaxel-Resistant Esophageal Squamous Cell Carcinoma

269 Clinical Impact of Bevacizumab in Patients with Relapsed Glioblastoma: Focus on a Real-Life Monocentric Survey (SV1 Study)